Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies

Fineline Cube Apr 11, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Bayer’s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors

Fineline Cube Apr 11, 2025

Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food...

Company Drug

Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome

Fineline Cube Apr 11, 2025

China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...

Company Deals

Astellas Pharma Partners with Shanghai Pharma on Zolbetuximab Commercialization

Fineline Cube Apr 11, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced a strategic partnership with Shanghai Pharmaceuticals (SPH; SHA:...

Company Drug

CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine

Fineline Cube Apr 11, 2025

China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...

Company Drug

Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials

Fineline Cube Apr 10, 2025

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...

Company Drug

Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China

Fineline Cube Apr 10, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...

Company Drug

HemaCell’s XJ-MK-002 Gains FDA Orphan Drug Designation for Giant Platelet Syndrome

Fineline Cube Apr 10, 2025

China-based Suzhou Xueji Biotechnology Co., Ltd (HemaCell), a pioneer in platelet regeneration-focused cell therapy, announced...

Company Drug

IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis

Fineline Cube Apr 10, 2025

China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...

Company Drug

Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China

Fineline Cube Apr 10, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis

Fineline Cube Apr 10, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Drug

Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy

Fineline Cube Apr 10, 2025

China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...

Company

GE Healthcare Appoints Jeannette Bankes as President and CEO of Patient Care Solutions

Fineline Cube Apr 10, 2025

GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced this week the appointment of Jeannette Bankes as...

Company Medical Device

Wantai Bio’s Tuberculosis Test Kit Joins UNOPS StopTB Procurement List

Fineline Cube Apr 10, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its Tuberculosis infection...

Company Drug

B. Braun’s DUPLEX System Approved by FDA for Piperacillin and Tazobactam

Fineline Cube Apr 10, 2025

B. Braun Medical Inc., a US-based healthcare company, announced that the U.S. Food and Drug...

Company Drug

Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies

Fineline Cube Apr 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...

Company Medical Device

Peijia Medical’s YonFlow Stent Approved by China’s NMPA

Fineline Cube Apr 10, 2025

Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...

Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Posts pagination

1 … 174 175 176 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.